Guardant Health, NRG Oncology to validate use of MRD assay in colon cancer trial
The NRG-GI005 study has been commenced to validate the clinical utility of Guardant Health’s molecular residual disease assay…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Jan 20
The NRG-GI005 study has been commenced to validate the clinical utility of Guardant Health’s molecular residual disease assay…
13 Jan 20
POSTECH University researchers have tested the new smart LED contact lenses on rabbits with diabetic retinopathy disease for…
13 Jan 20
The study has evaluated the use of radiotherapy in patients with bladder cancer which had spread to the…
13 Jan 20
Co-marketing partnership to drive awareness of ArcherDX IVD products and increase access to vital genomic information in the…
13 Jan 20
ProciseDx is a diagnostics company committed to the development and commercialization of a broad portfolio of point-of care…
13 Jan 20
Data quantifying the benefit of Sera’s PreTRM strategy submitted for scientific review
10 Jan 20
Provista is engaged in the development of blood-based proteomic diagnostic, prognostic and monitoring tests
10 Jan 20
Percept PC neurostimulator is claimed to be the only Deep Brain Stimulation (DBS) system commercially available in the…
10 Jan 20
Element intends to use the funds to speed the development of its low-cost, and easy-to-use genomic sequencing solutions
10 Jan 20
The Flow Re-Direction Endoluminal Device (FRED) System is indicated for use in the internal carotid artery from the…